Preeclampsia Overview and Unmet Need - Preeclampsia affects 5-8% of all pregnancies in the U S, impacting 180,000 to 300,000 patients annually[10] - Refractory hypertension drives approximately 50% of deliveries in early-onset preeclampsia cases[51] - Current anti-hypertensives primarily target vascular smooth muscle cells, managing symptoms but not addressing the underlying endothelial dysfunction[53] DM199 Mechanism of Action and Potential Benefits - DM199 aims to increase placental perfusion and repair endothelium, potentially reducing blood pressure[44] - DM199 is not expected to cross the placental barrier, offering a potential safety advantage compared to small molecules[46] - DM199 targets both upstream hypoxia and downstream endothelial dysfunction and blood pressure[44] - DM199 has the potential to safely extend gestation and accelerate fetal growth[45] DM199 Phase 2 Trial - The ongoing Phase 2, Part 1A investigator-sponsored trial is recruiting preeclampsia patients with planned delivery in less than 72 hours[58, 60] - The trial includes dose escalation to identify the optimal dose based on blood pressure reductions[59, 62] - Key endpoints include safety and tolerability, placental transfer analysis, blood pressure reduction, and dilation of intrauterine arteries[62]
DiaMedica Therapeutics (DMAC) Earnings Call Presentation